A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Pliant Therapeutics, Inc.
National Cancer Institute (NCI)
OncoC4, Inc.
Genmab
Mayo Clinic
Rutgers, The State University of New Jersey
Sotio Biotech Inc.